tuberculosis

[Immunity] Researchers defined crucial in vivo functions of the death receptor-mediated and BCL-2-regulated apoptosis pathways in mediating protection against tuberculosis by eliminating distinct populations of infected macrophages and neutrophils and priming T cell responses.

[Scientific Reports] An in-silico approach has been adopted to construct a multi-epitope vaccine from selected immunogenic extracellular vesicle proteins to elicit a cellular as well as a humoral immune response.

[Scientific Reports] Researchers demonstrated that prostaglandin E2 (PGE2) exerted a potent immunosuppressive action during the immune response of the human host against Mycobacterium tuberculosis infection.

[Nature Medicine] Investigators studied a patient with inherited PD-1 deficiency and tuberculosis who died of pulmonary autoimmunity. The patient’s leukocytes did not express PD-1 or respond to PD-1-mediated suppression.

[Praedicare Inc. (BusinessWire, Inc.)] Praedicare Inc., announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel Tuberculosis (TB) drug regimens using Praedicare’s in vitro hollow fiber model of TB in identifying potential new drug regimens that shorten treatment times for the disease.

[Journal of Clinical Investigation] To identify mechanisms of resistance to Mycobacterium tuberculosis (Mtb) infection, scientists compared transcriptional profiles from highly-exposed contacts who resist tuberculin skin test/interferon-γ release assay conversion and controls with latent Mtb infection using RNAseq.